Sure, having a cold or respiratory infection can temporarily make it harder to breathe. But if excessive coughing and ...

2, 2024 — The FDA has approved Regeneron and Sanofi’s drug ... COPD in the U.S. COPD is a long-term lung disease that makes breathing difficult and gets worse over time. It accounts for most ...

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

Foresee Pharma announces preliminary results from phase 1 trial, highlighting promising safety, tolerability and PK profile of linvemastat: Taipei, Taiwan Tuesday, October 22, 202 ...

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and ... and the most prescribed biologic by pulmonologists in the US Paris and Tarrytown, NY, ...

Treatment with dupilumab reduced the annualized rate of moderate or severe COPD exacerbations by 30% ... that of prior approved indications. The most common adverse events from both trials were ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD ... the most common adverse events (≥2%) more ...

The global Chronic Obstructive Pulmonary Disease (COPD) treatment market is projected to experience steady growth over the ...

Dupixent for the treatment of COPD has been approved in more than ... profile of Dupixent in its approved indications. The most common side effects across indications include injection site ...

A mother has paid tribute to her "one in a million" daughter who was "always laughing" following her tragic death aged 39.